Fosfomycin/metronidazole - Reponex Pharmaceuticals
Alternative Names: RNX-051Latest Information Update: 08 Aug 2024
At a glance
- Originator Reponex Pharmaceuticals
- Class Anti-infectives; Antibacterials; Antiprotozoals; Epoxy compounds; Esters; Nitroimidazoles; Organophosphorus compounds; Phosphonic acids; Phosphoric acid esters; Phosphoric Acids; Radiosensitisers; Skin disorder therapies; Small molecules
- Mechanism of Action Cell wall inhibitors; DNA synthesis inhibitors; Peptidoglycan inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Bacterial infections
Most Recent Events
- 01 Jul 2023 Reponex Pharmaceuticals in collaboration with Zealand University Hospital completes a Phase-II clinical trial in Bacterial infections in Denmark (Parenteral) (EudraCT 2019-000131-51) (NCT04312360)
- 14 Oct 2022 Fosfomycin/metronidazole is still in phase II trials for Bacterial infections in Denmark (NCT04312360)